Avidity Biosciences to Present New Duchenne Muscular Dystrophy Data at 2025 World Muscle Society Congress

Avidity Biosciences to Present New Duchenne Muscular Dystrophy Data at 2025 World Muscle Society Congress

By, Admin 7 October 2025

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company developing a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), announced that it will deliver late-breaking oral and poster presentations at the 30th Annual International Congress of the World Muscle Society (WMS), taking place October 7–11, 2025, in Vienna, Austria.

The presentations will expand on positive results shared in September 2025 showing reversal of disease progression and significant functional improvement in patients with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping (DMD44) treated for one year with delpacibart zotadirsen (del-zota) in the Phase 1/2 EXPLORE44® and Phase 2 EXPLORE44-OLE™ studies. Del-zota remains an investigational therapy and has not yet been approved by the FDA.

Key WMS 2025 Presentations

  • Oral Presentation: Delpacibart zotadirsen (del-zota) showed trends toward improvement in functional and patient-reported outcomes in DMD44
    Speaker: Dr. Kevin M. Flanigan, Nationwide Children’s Hospital
    Date/Time: October 11, 2025, 12:33–12:45 p.m. CET
  • Poster Presentation (674P): Delpacibart Zotadirsen (Del-zota) Increased Dystrophin and Improved Muscle Integrity Markers Regardless of Ambulatory Status in Individuals with DMD44
    Presenter: Dr. Aravindhan Veerapandiyan, University of Arkansas for Medical Sciences & Arkansas Children's Hospital
    Date/Time: October 8, 2025, 2:30–3:30 p.m. CET

About Avidity Biosciences

Avidity Biosciences aims to transform RNA therapeutics with its AOC™ platform, which merges monoclonal antibody precision with oligonucleotide-based therapies to target diseases previously unreachable by RNA technologies. The company is advancing clinical programs in:

  • Myotonic dystrophy type 1 (DM1)
  • Duchenne muscular dystrophy (DMD)
  • Facioscapulohumeral muscular dystrophy (FSHD)

Additionally, Avidity is expanding into rare genetic cardiomyopathies and developing programs in cardiology and immunology through strategic collaborations.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!